NCT04834557View on ClinicalTrials.gov

Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

May 18, 2022

Study Completion Date

September 30, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Placebo

Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

DRUG

Digoxin 0.25 mg

All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

DRUG

Ursodeoxycholic acid (UDCA) 500 mg

All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Trial Locations (1)

Unknown

Menoufia University Hospital, Shibīn al Kawm

All Listed Sponsors
lead

Tanta University

OTHER

NCT04834557 - Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter